期刊文献+

缬沙坦致不良反应74例文献分析 被引量:9

Adverse reactions induced by valsartan:analysis of 74 cases
原文传递
导出
摘要 目的:探讨缬沙坦不良反应发生的特点及规律,为临床合理用药提供参考。方法:通过对维普数据库和中国知网进行检索,并查阅原始文献,对2000-2009年国内期刊报道的74例缬沙坦所致不良反应进行统计分析。结果:缬沙坦的不良反应主要有头晕、头痛、刺激性干咳、血管神经性水肿、胃肠道反应、首剂低血压、一过性低血压、关节痛等。结论:临床医师应关注缬沙坦所致的不良反应,以确保临床用药安全、合理、有效。 Objective:To evaluate the patterns and characteristics of adverse reactions induced by valsartan and to provide guidance for its rational use in clinic. Methods:A total of 74 patients with adverse reactions induced by valsartan were retrieved and analyzed statistically. These cases were reported in domestic pharmaceutical journals between 2000 and 2009,and searched from VIP Database and CNKI. Results:The main adverse reactions induced by valsartan included dizziness,headache,dry cough,acute circumscribed edema,gastrointestinal tract reactions,hypotension,and arthralgia. Conclusion:Clinicians should pay attention to adverse reactions induced by valsartan to ensure rational,safe and effective use of valsartan.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第12期1094-1096,共3页 Chinese Journal of New Drugs
关键词 缬沙坦 不良反应 文献分析 valsartan adverse reaction(ADR) literature analysis
  • 相关文献

参考文献10

  • 1GUTHRIE R. Recent advances in cardiovascular risk reduction: implications of ONTARGET [ J ]. Clin Cornerstone, 2009, 9 ( Suppl 3 ) : S18 - S26.
  • 2陈华茜,刘巍,黄云芳,赵黎,杨涛.大剂量缬沙坦治疗慢性肾病的安全性研究[J].医药导报,2006,25(8):785-787. 被引量:3
  • 3金振一,李华,丁大植,秦孝智,崔兰,沈铁宽.缬沙坦联合培哚普利治疗慢性充血性心力衰竭的临床疗效及安全性[J].中国心血管病研究,2004,2(8):608-610. 被引量:2
  • 4BISSESSOR N, WHITE H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction [J].Vasc Health Risk Manag, 2007,3 (4) :425 - 430.
  • 5MESSERLI FH, GROSSMAN E. Therapeutic controversies in hypertension [ J ]. Semin Nephrol,2005,25 (4) :227 - 235.
  • 6FERRI C, CROCE G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine[J]. Adv Ther, 2008,25(4) :300 -320.
  • 7BASILE G, VILLARI D, GANGEMI S, et al. Candesartan cilexetil-induced severe hepatotoxicity[ J]. J Clin Gastroenterol, 2003,36(3) :273 -275.
  • 8BOSCH X. Losartan-induced hepatotoxicity[J].JAMA, 1997, 278(19) :1572.
  • 9ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al. Cholestatic hepatitis related to use of irbesartan : a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity [ J ]. Eur J Gastroenterol ttepatol, 2002,14 ( 8 ) : 887 - 890.
  • 10FRYE CB, PETTIGREW TJ. Angioedema and photosensitive rash induced by valsartan[ J]. Pharmacotherapy, 1998,18 (4) : 866 - 868.

二级参考文献19

  • 1[1]Kodama M,Tachilawa H,Kashimura T,et al.Effects of humoral factors on left ventricular remodeling under chronic heart failure[J ].Nippon Yakurigajku Zasshi,2004,123(2):63-70
  • 2[2]Wiley G,Cole C.Candesartan reduces cardiovascular death in CHF patients on ACE inhibitor [ J ] J Fam Pract,2004,53(2):93-94
  • 3[3]Brunner HP,Rocca MD,Vaddadi G,et al.Recent insight into therapy of congestive heart failure:Focus on ACE inhibiton and angiotension-Ⅱ antagonoism[J ].J Am Coll Cardiol,1999,33:163-173
  • 4[4]Tanemoto M,Abe T,Obara N,et al.Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor blocker [ J ].Hypertens Res,2003,26(10):863-868
  • 5Gansevoort R T, Sluiter W J, Hemmelder H, et al. Antiproteinuric effect of blood-pressure-lowering agents : A meta-analysis of comparative trials [ J ]. Nephrol Dial Transplant, 1995,10 ( 11 ) :1963 - 1974.
  • 6Uggeneti P, Schieppati A, Remuzzi G. Proggression, remission, regression of chronic renal disease [J]. Lancet, 2001,357 ( 9268 ):1601 - 1608.
  • 7Eir M R. Are drugs that block the rennin-angiotensin system effective and safe in patients with renal insufficiency? [J]. Am J Hypertens,1999,12(3):195 -203.
  • 8Weinberg M S,Weinberg A J,Cord R,et al. The effect of angiotensin Ⅱ receptor blockade beyond maximal recommended doses in reducing urinary protein excretion [ J ]. J Renin Angiotensin Aldosterone Syst ,2001,2(Suppl 1 ) :196 - 198.
  • 9Jafar T H, Schmid C H, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic rena disease. A meta-analysis of patient level data [J].Ann Intern Med,2001,135 (2) :73 - 87.
  • 10Parving H H, Lehert H, Brochner M J, et al. For the Irbersartan in patients with type 2 diabetes and microalbuminuria study group: The effect of irbersartan on the the development of diabetic nephropathy in patient with type 2 diabetes[J]. N Engl J Med,2001,345 (12):870 - 878.

共引文献3

同被引文献77

引证文献9

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部